[Systemic complications in patients with rheumatism and collagen disease and their treatment].
Eguchi
Katsumi
K
D000686:Amyloidosis / Q000209:etiology* / Q000628:therapy; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000209:etiology* / Q000628:therapy; D003095:Collagen Diseases / Q000150:complications* / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010024:Osteoporosis / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011239:Prednisolone / Q000009:adverse effects / Q000627:therapeutic use; D012216:Rheumatic Diseases / Q000150:complications* / Q000628:therapy
D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D011239:Prednisolone